(Q37707412)

22 August 2017

1 reference

title

High-density lipoproteins and cardiovascular disease: 2010 update (English)

1 reference

22 August 2017

1 reference

cardiovascular disease

1 reference

4

Jacques Genest

1 reference

22 August 2017

Khalid Alwaili

1

1 reference

22 August 2017

Zuheir Awan

series ordinal

2

1 reference

22 August 2017

Ali Alshahrani

series ordinal

3

1 reference

22 August 2017

publication date

1 March 2010

1 reference

Expert Review of Cardiovascular Therapy

22 August 2017

published in

1 reference

22 August 2017

volume

8

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

413-423

1 reference

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

22 August 2017

cites work

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.

21 January 2018

1 reference

The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes.

21 January 2018

1 reference

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

Antiinflammatory properties of HDL.

21 January 2018

1 reference

Atheroprotective effects of high-density lipoproteins

21 January 2018

1 reference

Endothelial and antithrombotic actions of HDL.

21 January 2018

1 reference

High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function

21 January 2018

1 reference

Transendothelial lipoprotein transport and regulation of endothelial permeability and integrity by lipoproteins

21 January 2018

1 reference

The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis

21 January 2018

1 reference

Update on strategies to increase HDL quantity and function

21 January 2018

1 reference

Intestinal ABCA1 directly contributes to HDL biogenesis in vivo

21 January 2018

1 reference

Molecular and cellular physiology of apolipoprotein A-I lipidation by the ATP-binding cassette transporter A1 (ABCA1).

21 January 2018

1 reference

Apolipoprotein A-I activates cellular cAMP signaling through the ABCA1 transporter

21 January 2018

1 reference

Double Superhelix Model of High Density Lipoprotein

21 January 2018

1 reference

Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles

21 January 2018

1 reference

Quantitative analysis of ABCA1-dependent compartmentalization and trafficking of apolipoprotein A-I: implications for determining cellular kinetics of nascent high density lipoprotein biogenesis

21 January 2018

1 reference

Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease

21 January 2018

1 reference

Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review

21 January 2018

1 reference

Functional mutations of the ABCA1 gene in subjects of French-Canadian descent with HDL deficiency

21 January 2018

1 reference

Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol

21 January 2018

1 reference

Multilevel regulation of leptin storage, turnover, and secretion by feeding and insulin in rat adipose tissue

21 January 2018

1 reference

Carboxyl-terminal disulfide bond of acid sphingomyelinase is critical for its secretion and enzymatic function.

21 January 2018

1 reference

Fine mapping and association studies of a high-density lipoprotein cholesterol linkage region on chromosome 16 in French-Canadian subjects

21 January 2018

1 reference

Genetic variation at the proprotein convertase subtilisin/kexin type 5 gene modulates high-density lipoprotein cholesterol levels

21 January 2018

1 reference

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I

21 January 2018

1 reference

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study

21 January 2018

1 reference

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

21 January 2018

1 reference

Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review

21 January 2018

1 reference

Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials

21 January 2018

1 reference

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review

21 January 2018

1 reference

Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis

21 January 2018

1 reference

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies

21 January 2018

1 reference

Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

21 January 2018

1 reference

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

21 January 2018

1 reference

Safety and tolerability of dalcetrapib

21 January 2018

1 reference

Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats

21 January 2018

1 reference

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

21 January 2018

1 reference

Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community

21 January 2018

1 reference

Molecular regulation of HDL metabolism and function: implications for novel therapies

21 January 2018

1 reference

High-density lipoprotein as a therapeutic target: a systematic review

21 January 2018

1 reference

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

21 January 2018

1 reference

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

21 January 2018

1 reference

The therapeutic potential of high-density lipoprotein mimetic agents in coronary artery disease

21 January 2018

1 reference

An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide

21 January 2018

1 reference

Transcriptional regulatory networks in lipid metabolism control ABCA1 expression

21 January 2018

1 reference

Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders

21 January 2018

1 reference

Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor.

21 January 2018

1 reference

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens

21 January 2018

1 reference

Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production

21 January 2018

1 reference

Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels

21 January 2018

1 reference

Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis

21 January 2018

1 reference

Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates

21 January 2018

1 reference

Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease

21 January 2018

1 reference

Elevated high-density lipoprotein (HDL) levels due to hepatic lipase mutations do not reduce cardiovascular disease risk: another strike against the HDL dogma

21 January 2018

1 reference

Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).

21 January 2018

1 reference

Identification of an ABCA1-dependent phospholipid-rich plasma membrane apolipoprotein A-I binding site for nascent HDL formation: implications for current models of HDL biogenesis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERC.10.4

1 reference

22 August 2017

1 reference